FDA: We Are Addressing IV Fluid Shortage

By Ed Miseta, Chief Editor, Clinical Leader

In a release from the FDA this morning, the agency is reporting that it is aware of the shortage situation existing for intravenous (IV) solutions, particularly 0.9% sodium chloride injection (i.e., saline). This solution is used to provide necessary fluids to patients with hydration and other conditions. FDA notes a range of factors may be responsible for the shortage, including increased hospital visits of patients experiencing symptions related to the current flu season.

There are three primary manufacturers of IV fluids: Baxter Healthcare Corp., B.Braun Medical Inc., and Hospira Inc. FDA notes it is currently working with all three manufacturers to help preserve the supply of product. Noting that millions of these I.V. products are used each week by health care providers, FDA believes addressing the shortage will depend on the continued increased demand for the product, as well as the manufacturing production of existing suppliers.

 Per the release: FDA remains committed to doing everything we can to address drug shortages, including finding alternative sources, so that patients can get the medicines they need when they need them.

FDA recommends continuing to visit the drug shortage webpage for updates. For additional information, customers can also contact the firms directly.